EMA to review PTC's ataluren

PTC Therapeutics Inc. (South Plainfield, N.J.) said EMA accepted for review an MAA seeking conditional approval of ataluren to treat nonsense mutation Duchenne muscular dystrophy (DMD). The applicatio...